Stephen Tyring
Advanced in Bullae

Dr. Stephen Tyring

Dermatology
Houston Skin Cancer Associates PLLC
451 N Texas Ave, 
Webster, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Bullae
Houston Skin Cancer Associates PLLC
451 N Texas Ave, 
Webster, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Tyring is a Dermatologist in Webster, Texas. Dr. Tyring is rated as an Advanced provider by MediFind in the treatment of Bullae. His top areas of expertise are Shingles, Plaque Psoriasis, Psoriasis, and Warts.

His clinical research consists of co-authoring 359 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Bullae.

Specialties
Dermatology
Licenses
Dermatology in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EMI Health
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 25 Less Insurance Carriers -

Locations

Houston Skin Cancer Associates Pllc
451 N Texas Ave, Webster, TX 77598
Call: 281-333-3376
Other Locations
Houston Skin Association - Pearland
10907 Memorial Hermann Dr Ste 170, Pearland, TX 77584
Call: 281-333-3376

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
Enrollment Status: Recruiting
Publish Date: December 05, 2025
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: April 26, 2024
Intervention Type: Drug, Biological
Study Drug: ASLAN004
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug, Biological
Study Drug: CDX-0159
Study Phase: Phase 1
A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
Enrollment Status: Completed
Publish Date: November 10, 2022
Intervention Type: Drug
Study Drug: Apremilast
Study Phase: Phase 4
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
Enrollment Status: Terminated
Publish Date: April 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients With Moderate to Severe Chronic Plaque Psoriasis
A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

359 Total Publications

Sweet syndrome successfully treated with upadacitinib.
Sweet syndrome successfully treated with upadacitinib.
Journal: JAAD case reports
Published: October 27, 2025
View All 359 Publications
Similar Doctors
Advanced in Bullae
Dr. Rachel Schmidtberger
Dermatology
Advanced in Bullae
Dr. Rachel Schmidtberger
Dermatology

Office

21800 Katy Fwy Ste 200, 
Katy, TX 
 (42.0 miles away)
713-771-1100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rachel Schmidtberger is a Dermatologist in Katy, Texas. Dr. Schmidtberger is rated as a Distinguished provider by MediFind in the treatment of Bullae. Her top areas of expertise are Sunburn, Psoriasis, Warts, and Actinic Keratosis.

Advanced in Bullae
Dr. Joseph Sedrak
Dermatology
Advanced in Bullae
Dr. Joseph Sedrak
Dermatology

Office

4101 Greenbriar Dr Ste 305, 
Houston, TX 
 (22.2 miles away)
346-888-4400
Languages Spoken:
English
See accepted insurances

Joseph Sedrak is a Dermatologist in Houston, Texas. Dr. Sedrak is rated as a Distinguished provider by MediFind in the treatment of Bullae. His top areas of expertise are Sunburn, Eschar, Squamous Cell Skin Carcinoma, and Kaposiform Hemangioendothelioma.

Advanced in Bullae
Dr. Vicky Z. Ren
Dermatology
Advanced in Bullae
Dr. Vicky Z. Ren
Dermatology

Baylor College Of Medicine - Dermatology

1977 Butler Blvd, Ste E6.200-1, 
Houston, TX 
 (19.7 miles away)
713-798-7620
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vicky Ren, MD, is dedicated to delivering high-quality, compassionate care to Houston and nearby communities. Vicky Ren specializes in Dermatology and works at BCM Dermatology. To make an appointment, please call (713) 798-7620. To review all accepted insurance carriers, please visit: https://www.stlukeshealth.org/patients-visitors/patients/billing-insurance/insurances-accepted. Dr. Ren is rated as an Advanced provider by MediFind in the treatment of Bullae. Her top areas of expertise are Bullae, Melanoma, DRESS Syndrome, and Actinic Keratosis.

VIEW MORE BULLAE DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tyring's expertise for a condition
ConditionClose
  • Elite
  • Acne
    Dr. Tyring is
    Elite
    . Learn about Acne.
    See more Acne experts
  • Merkel Cell Carcinoma
    Dr. Tyring is
    Elite
    . Learn about Merkel Cell Carcinoma.
    See more Merkel Cell Carcinoma experts
  • Plaque Psoriasis
    Dr. Tyring is
    Elite
    . Learn about Plaque Psoriasis.
    See more Plaque Psoriasis experts
  • Psoriasis
    Dr. Tyring is
    Elite
    . Learn about Psoriasis.
    See more Psoriasis experts
  • Shingles
    Dr. Tyring is
    Elite
    . Learn about Shingles.
    See more Shingles experts
  • Warts
    Dr. Tyring is
    Elite
    . Learn about Warts.
    See more Warts experts
  • Distinguished
  • Actinic Keratosis
    Dr. Tyring is
    Distinguished
    . Learn about Actinic Keratosis.
    See more Actinic Keratosis experts
  • Atopic Dermatitis
    Dr. Tyring is
    Distinguished
    . Learn about Atopic Dermatitis.
    See more Atopic Dermatitis experts
  • Epidermodysplasia Verruciformis
    Dr. Tyring is
    Distinguished
    . Learn about Epidermodysplasia Verruciformis.
    See more Epidermodysplasia Verruciformis experts
  • Genital Warts
    Dr. Tyring is
    Distinguished
    . Learn about Genital Warts.
    See more Genital Warts experts
  • Seborrheic Keratosis
    Dr. Tyring is
    Distinguished
    . Learn about Seborrheic Keratosis.
    See more Seborrheic Keratosis experts
  • Advanced
  • Acrospiroma
    Dr. Tyring is
    Advanced
    . Learn about Acrospiroma.
    See more Acrospiroma experts
  • Autoerythrocyte Sensitivity
    Dr. Tyring is
    Advanced
    . Learn about Autoerythrocyte Sensitivity.
    See more Autoerythrocyte Sensitivity experts
  • Autosomal Recessive Hypotrichosis
    Dr. Tyring is
    Advanced
    . Learn about Autosomal Recessive Hypotrichosis.
    See more Autosomal Recessive Hypotrichosis experts
  • Basal Cell Skin Cancer
    Dr. Tyring is
    Advanced
    . Learn about Basal Cell Skin Cancer.
    See more Basal Cell Skin Cancer experts
  • Benign Chronic Pemphigus
    Dr. Tyring is
    Advanced
    . Learn about Benign Chronic Pemphigus.
    See more Benign Chronic Pemphigus experts
  • Bullae
    Dr. Tyring is
    Advanced
    . Learn about Bullae.
    See more Bullae experts
View All 28 Advanced Conditions
  • Experienced
  • Acute Febrile Neutrophilic Dermatosis
    Dr. Tyring is
    Experienced
    . Learn about Acute Febrile Neutrophilic Dermatosis.
    See more Acute Febrile Neutrophilic Dermatosis experts
  • Alopecia Areata
    Dr. Tyring is
    Experienced
    . Learn about Alopecia Areata.
    See more Alopecia Areata experts
  • Anaplastic Large Cell Lymphoma
    Dr. Tyring is
    Experienced
    . Learn about Anaplastic Large Cell Lymphoma.
    See more Anaplastic Large Cell Lymphoma experts
  • Athlete's Foot
    Dr. Tyring is
    Experienced
    . Learn about Athlete's Foot.
    See more Athlete's Foot experts
  • Bowen's Disease
    Dr. Tyring is
    Experienced
    . Learn about Bowen's Disease.
    See more Bowen's Disease experts
  • Bullous Pemphigoid
    Dr. Tyring is
    Experienced
    . Learn about Bullous Pemphigoid.
    See more Bullous Pemphigoid experts
View All 87 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.